老年局限性前列腺癌的放射治疗:一项系统性文献综述
年龄常成为根治性治疗的障碍并导致治疗不足,但老年患者接受外照射放疗或联合近距离放疗推量后肿瘤学结局与年轻患者相当,晚期毒性低;超高龄(>80岁)患者接受近距离放疗推量后观察到泌尿系统毒性过高,ADT的使用应结合合并症考量。
要点
- 「老年患者」的定义在70至80岁之间不等,各队列使用的主要终点不一致影响分析。
- 老年患者接受外照射放疗或联合近距离放疗推量后肿瘤学结局与年轻患者相当,晚期毒性率低。
- 超高龄(>80岁)患者接受近距离放疗推量后观察到泌尿系统毒性过高,ADT使用应结合合并症考量。
核心结论
- 由于预期寿命增加,老年前列腺癌的管理对患者、临床医生和医疗保险支付方均是挑战。
- 除不适合的患者外,老年患者经肿瘤老年评估后仍是根治性治疗的候选者(即不论年龄)。
- 需要在专门针对该人群开展的前瞻性试验中获取更可靠的数据,以为日常临床实践提供更好的指导。
研究设计与样本
- 分析176篇文献后,24篇符合选择标准。
- 分析主要聚焦老年患者的治疗不足问题及放疗的获益/风险平衡。
主要发现
- 「老年患者」的定义在70至80岁之间不等。
- 各队列使用的主要终点不一致影响了分析。
- 年龄常成为根治性治疗的障碍,随之带来治疗不足的风险,尤其是在预后较差的患者中。
- 老年患者接受单纯外照射放疗或联合近距离放疗推量后,肿瘤学结局与年轻患者相当。
- 晚期毒性率低,且多数与年轻人群相当;但超高龄(>80岁)患者接受近距离放疗推量后观察到泌尿系统毒性过高。
关键数值与推荐
- 「老年患者」的定义在各文献中为70至80岁不等。
- 超高龄定义为>80岁,该组接受近距离放疗推量后观察到泌尿系统毒性过高。
- ADT的使用应结合合并症考量,在某些患者中甚至可能有害。
临床怎么用
- 除不适合的患者外,老年患者经肿瘤老年评估后仍是根治性治疗的候选者(即不论年龄)。
- ADT的使用应结合合并症考量,在某些患者中甚至可能有害。
- 作者指出,需要专门针对该人群开展的前瞻性试验提供更可靠的数据,以更好地指导日常临床实践。
局限性
- 「老年患者」的定义在70至80岁之间不等。
- 各队列使用的主要终点不一致影响了分析。
- 需要在专门针对该人群开展的前瞻性试验中获取更可靠的数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To analyze the literature that addresses radiation therapy for intermediate and high-risk prostate cancer (PC) in the elderly. PATIENTS AND METHODS: A PubMed literature search was conducted including articles from 01/01/2000 to 30/06/21, with the following keywords: PC, radiotherapy/brachytherapy and elderly. The analysis mainly focused on the issue of under-treatment in the elderly and the benefit/risk balance of irradiation. RESULTS: Of the 176 references analyzed, 24 matched the selection criteria. The definition of "elderly patient" varied from 70 to 80 years. The analysis was impacted by the inhomogeneous primary end points used in each cohort. Age was often an obstacle to radical treatment, with a subsequent risk of under-treatment, particularly in patients with a poorer prognosis. However, comparable elderly oncological outcomes were compared to younger patients, both with external beam radiotherapy alone or combined with brachytherapy boost. Late toxicity rates are low and most often comparable to younger populations. However, a urinary over- toxicity was observed in the super-elderly (>80 years) after brachytherapy boost. The use of ADT should be considered in light of comorbidities, and may even be deleterious in some patients. CONCLUSION: Due to the increase in life expectancy, the management of PC in the elderly is a challenge for patients, clinicians and health insurance payers. Except for unfit men, elderly patients remain candidates for optimal curative treatment (i.e. regardless of age) after oncogeriatric assessment. More solid data from prospective trials conducted specially in this population will provide better guidance in our daily clinical practice.
引用
- Marotte D, Chand-Fouche ME, Boulahssass R, et al. Irradiation of localized prostate cancer in the elderly: A systematic literature review. Clin Transl Radiat Oncol. 2022. PMID: 35492872. doi:10.1016/j.ctro.2022.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。